Richard A Manning
Overview
Explore the profile of Richard A Manning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jones M, Murden S, Brooks C, Maloney V, Manning R, Gilmour K, et al.
BMC Med Genet
. 2013 Apr;
14:42.
PMID: 23557002
Background: Hermansky-Pudlak syndrome 2 (HPS2; OMIM #608233) is a rare, autosomal recessive disorder caused by loss-of-function genetic variations affecting AP3B1, which encodes the β3A subunit of the adaptor-related protein complex...
2.
Shapiro S, Phillips E, Manning R, Morse C, Murden S, Laffan M, et al.
Br J Haematol
. 2012 Oct;
160(2):220-7.
PMID: 23061815
Heritable dysfibrinogenaemia (HD) is a rare qualitative disorder of fibrinogen (FGN). To better describe the clinical, laboratory and genotypic spectrum of HD, we evaluated 35 subjects identified at two UK...
3.
Livesey J, Manning R, Meek J, Jackson J, Kulinskaya E, Laffan M, et al.
Thorax
. 2011 Dec;
67(4):328-33.
PMID: 22169361
Background: Elevated plasma levels of coagulation factor VIII are a strong risk factor for pulmonary emboli and deep venous thromboses. Objectives: To identify reversible biomarkers associated with high factor VIII...
4.
Uprichard J, Manning R, Laffan M
Br J Haematol
. 2010 Mar;
149(4):613-9.
PMID: 20230412
The anticoagulant effect of unfractionated heparin (UFH) is monitored using the activated partial thromboplastin time (APTT). An APTT of 1.5-2.5 times the control is usually taken as the therapeutic range...
5.
Shovlin C, Angus G, Manning R, Okoli G, Govani F, Elderfield K, et al.
PLoS One
. 2010 Feb;
5(2):e9154.
PMID: 20174619
Background: Coagulation factor VIII (FVIII) deficiency leads to haemophilia A. Conversely, elevated plasma levels are a strong predictor of recurrent venous thromboemboli and pulmonary hypertension phenotypes in which in situ...
6.
Cunningham N, Laffan M, Manning R, ODonnell J
Blood Coagul Fibrinolysis
. 2005 Sep;
16(7):465-8.
PMID: 16175004
Elevated factor VIII coagulant activity (FVIII:C) levels (>150 IU/dl) represent a prevalent independent risk factor for venous thromboembolism (VTE). Low-density lipoprotein receptor-related protein (LRP) is involved in factor VIII clearance...
7.
ODonnell J, Manning R, Laffan M
Br J Haematol
. 2003 Sep;
123(1):139-41.
PMID: 14510956
Beta-blockers significantly reduce elevated factor VIII (FVIII) levels in patients with venous thromboembolism (VTE). To determine whether beta-adrenergic receptors are important in the aetiology of high FVIII levels, we investigated...
8.
Mumford A, Laffan M, ODonnell J, McVey J, Johnson D, Manning R, et al.
Br J Haematol
. 2002 Jul;
118(2):589-94.
PMID: 12139751
The interdomain acidic region a1 is a unique structural feature of coagulation factor VIII (FVIII) and may mediate the proteolytic activation of FVIII and the inactivation of FVIIIa. We report...
9.
ODonnell J, Boulton F, Manning R, Laffan M
Br J Haematol
. 2002 Feb;
116(2):350-6.
PMID: 11841438
Previous reports on the effect of Secretor and Lewis blood groups on plasma factor VIII-von Willebrand factor (FVIII-VWF) levels have produced conflicting findings. To determine whether either or both loci...
10.
ODonnell J, Boulton F, Manning R, Laffan M
Arterioscler Thromb Vasc Biol
. 2002 Feb;
22(2):335-41.
PMID: 11834538
To investigate whether the effect of ABO blood group on plasma von Willebrand factor (vWF) levels is mediated by the ABH antigenic determinants carried on N-linked glycans of vWF, we...